About Event
What You Missed at the Inaugural Cell & Gene Therapy Pricing & Reimbursement Summit
Cell and gene therapies represent a promising evolution in medical treatment, offering the potential for not only curative interventions but also long-term remission rates. As these ground-breaking treatments emerge onto the market, they raise a crucial question: how can we ensure fair and inclusive access while navigating the intricate landscape of coverage and payment?
Introducing the inaugural The Cell & Gene Therapy Pricing & Reimbursement Summit an exclusive gathering designed to cultivate open dialogue and collaboration among key stakeholders in pricing, reimbursement, and market access within the healthcare ecosystem. Leaders from biotech, pharma, physicians, healthcare providers, regulatory bodies, and government agencies, all dedicated to ensuring efficient, scalable, and accessible access to these life-changing advanced therapies gathered. You would've heard from key opinion leaders and gained insights into the potential impact of the Inflation Reduction Act, explored the latest cell and gene pricing model proposed by CMS, and co-created more effective pricing and reimbursement strategies, to enhance patient access and boost the success of a commercial cell and gene therapy launch.
DISCOVER
ENGAGE
GAIN
how leading companies are navigating the evolving regulatory landscape to tackle complex challenges and gain strategic insights
with industry experts to enhance patient access and ensure the success of commercial cell and gene therapy launches
knowledge into the impact of the IRA and the latest pricing models
The Highlights From Our 2024 Pricing, Market Access & Reimbursement Experts:
Analyzing the implications of the Cell and Gene Therapy Access Model proposed by the CMMI and its alignment with the IRA provisions to understand the commercial strategy implications and develop actionable insights for navigating the evolving landscape of cell and gene therapy pricing negotiations with Novartis
Delving into the postlaunch landscape of cell and gene therapies, and gain insights into their Commercialization by learning from real-world examples of how public payment structures have unfolded across different states, enabling you to adapt strategies to diverse regulatory environments, with insights from Orca Bio
Unravelling the complexities surrounding the challenge of making profits in the current cell and gene therapy landscape by addressing and overcoming challenges in the manufacturing process to reduce costs and increase drug profitability to achieve sustainable growth with insights from Ultragenyx and Pfizer
Expanding knowledge of the integration of single or multiple public and private payers in payment policies to understand the responses of payers in providing access to these transformative therapies, enabling you to tailor your approach for better collaboration with insights from Gilead Sciences
Exploring innovative alternatives to the traditional buy and bill model, providing you with strategic insights into evolving approaches to product delivery and reimbursement to master the intricacies of engaging with the diverse array of payers in the US landscape with insights from Janssen Pharmaceutical Companies of Johnson & Johnson and bluebird bio
What Our Speakers Had to Say:
“Aligning on key market trends, identifying challenges to access, particularly from a reimbursement standpoint, and developing potential solutions to these challenges are all critical to ensuring individuals may benefit from the transformational innovation of novel cell and gene therapies.”
Laura Okpala, Executive Director, US Reimbursement Policy, Gilead Sciences